Have you suffered a stroke or myocardial infraction (MI), also known as a heart attack? Are you overweight? If so, you may be eligible to enroll in our upcoming clinical trial. This trial is set to begin in October 2018. We will be evaluating the cardiovascular outcomes of the injectable drug, semaglutide, in patients with prior MI, stroke and peripheral arterial disease.
Semaglutide is an FDA approved drug that reduces blood sugar levels, weight and cardiovascular events in diabetic patients.. The current study is looking to see it’s long term impact on patients that have not been previously been diagnosed with diabetes, but have had a cardiovascular event.
We are looking for motivated, serious patients, as this trial is expected to last 54 months, including a seven week follow-up period. During the trial you will be making approximately 25 visits to our clinic in Ventura, and you will need to take a once-weekly injection.
Our team is committed to your health and will gladly work with your current care team to update them on your health throughout the process. We will also compensate you for your time and transportation expenses.
Please read the following checklist of all qualifications for the upcoming trial:
- MI or stroke greater than 60 days ago
- Male or female, 45 years of age or older
- A BMI greater than 27
- HbA1c less than 6.5%
- No history of type 1 or type 2 diabetes
- No treatment with glucose lowering agents in the past 90 days
If you believe you meet all of the above, we’d love to hear from you. You can call our office at (805) 658-8460 or send us an email at firstname.lastname@example.org to schedule an introductory meeting. At this time, we are scheduling enrollment appointments with patients that are interested in participating. While the trial is set to begin shortly, the enrollment period will continue through 2021, and we are always seeking new participants for our studies.